SHANGHAI SHYNDEC PHARMACEUTICAL CO., LTD. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 10.57 CNY | -0.38% |
|
+0.76% | +7.97% |
| 04-16 | Shyndec Pharmaceutical's Unit Gets Nod to Market Empagliflozin Tablets | MT |
| 04-15 | China stocks rise after new guidelines; HK shares drop | RE |
| Sales 2024 * | 13.35B 1.85B 147B | Sales 2025 * | 14.69B 2.03B 162B | Capitalization | 14.18B 1.96B 156B |
|---|---|---|---|---|---|
| Net income 2024 * | 863M 119M 9.51B | Net income 2025 * | 996M 138M 10.98B | EV / Sales 2024 * | 1.06 x |
| Net cash position 2024 * | - 0 0 | Net cash position 2025 * | - 0 0 | EV / Sales 2025 * | 0.97 x |
| P/E ratio 2024 * |
16.6
x | P/E ratio 2025 * |
14.3
x | Employees | 11,608 |
| Yield 2024 * |
14.1% | Yield 2025 * |
17% | Free-Float | 39.64% |
More Fundamentals
* Assessed data
More news
| 1 day | -0.38% | ||
| 1 week | +0.76% | ||
| Current month | +18.23% | ||
| 1 month | +18.63% | ||
| 3 months | +15.90% | ||
| 6 months | +2.82% | ||
| Current year | +7.97% |
1 week
10.15
10.76
1 month
8.5310.76
Current year
7.6110.76
1 year
7.6113.91
3 years
7.6114.30
5 years
7.6114.30
10 years
7.6130.33
| Managers | Title | Age | Since |
|---|---|---|---|
Wan Yong Lian
PSD | President | 54 | 23/09/22 |
Hao Li
DFI | Director of Finance/CFO | 59 | 17/11/16 |
Qian Yin Jing
IRC | Investor Relations Contact | 44 | 12/09/19 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Yong Gang Xing
CHM | Chairman | 48 | 24/11/19 |
Yong Liu
BRD | Director/Board Member | 55 | 16/05/21 |
Shu Yuan Wei
BRD | Director/Board Member | 60 | 28/05/20 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.00% | 34 M€ | +2.67% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 28/04/24 | 10.57 | -0.38% | 22 573 410 |
| 26/04/24 | 10.61 | -0.66% | 24,159,470 |
| 25/04/24 | 10.68 | +2.69% | 32,644,090 |
| 24/04/24 | 10.4 | +0.39% | 26,739,850 |
| 23/04/24 | 10.36 | -1.52% | 24,845,240 |
End-of-day quote Shanghai S.E., April 28, 2024
More quotes
SHANGHAI SHYNDEC PHARMACEUTICAL CO., LTD. is a China-based company principally engaged in the research and development, production and sales of pharmaceutical products. The Company's main products are antibiotics, circulatory system drugs and biological products, including garlic oil soft capsules, lecithin soft capsules and deep-sea fish oil soft capsules. Its bulk pharmaceutical chemicals (BPCs) include macrolide antibiotics, antiviral, anti-tumor, cardiovascular, hormones and weight loss drugs. The Company also offers topical preparations, such as gynecological suppositories and dermatology preparations.
Sector
Pharmaceuticals
Calendar
29/04/2024
- Q1 2024 Earnings Release
Sell
Buy
Mean consensus
HOLD
Number of Analysts
1
Last Close Price
10.61
Average target price
-
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +7.97% | 1.96B | |
| +4.06% | 70.44B | |
| +10.97% | 8.94B | |
| -16.83% | 4.75B | |
| +43.48% | 4.5B | |
| +3.20% | 3.85B | |
| +23.46% | 2.38B | |
| -21.36% | 2.34B | |
| -27.04% | 2.2B | |
| -0.50% | 1.64B |
- Stock Market
- Equities
- 600420 Stock
